Rolf Larsson

Pharmacokinetic models for the saturable distribution of paclitaxel.

M O Karlsson, J. Bergh, M. Karlsson, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

K. Nilsson, R. Larsson, P. Nygren, 1996, British Journal of Cancer.

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

R. Larsson, P. Nygren, H. Fridborg, 1997, British Journal of Cancer.

Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.

J. Bergh, R. Larsson, P. Nygren, 1991, British Journal of Cancer.

Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.

B. Jonsson, R. Larsson, P. Nygren, 2000, European journal of cancer.

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Claes R. Andersson, M. Jarvius, M. Fryknäs, 2024, BMC pharmacology & toxicology.

The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro–from cytotoxic synergy to complete inhibition of apoptosis

R. Larsson, P. Nygren, S. Ekelund, 2002, British journal of pharmacology.